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Introduction: Mesenchymal stem cells (MSCs) are a promising source of cells for regenerative therapies. Although
they can be isolated easily from several tissues, cell expansion is limited since their properties are lost with
successive passages. Hence, pluripotent derived MSCs (PD-MSCs) arise as a suitable alternative for MSC production.
Nevertheless, at present, PD-MSC derivation protocols are either expensive or not suitable for clinical purposes.
Methods: In this work we present a therapy-grade, inexpensive and simple protocol to derive MSCs from
pluripotent stem cells (PSCs) based on the use of platelet lysate (PL) as medium supplement.
Results: We showed that the PD-MSCPL expressed multiple MSC markers, including CD90, CD73, CD105, CD166,
and CD271, among others. These cells also show multilineage differentiation ability and immunomodulatory effects
on pre-stimulated lymphocytes. Thorough characterization of these cells showed that a PD-MSCPL resembles an
umbilical cord (UC) MSC and differs from a PSC in surface marker and extracellular matrix proteins and integrin
expression. Moreover, the OCT-4 promoter is re-methylated with mesenchymal differentiation comparable with the
methylation levels of UC-MSCs and fibroblasts. Lastly, the use of PL-supplemented medium generates significantly
more MSCs than the use of fetal bovine serum.
Conclusions: This protocol can be used to generate a large amount of PD-MSCs with low cost and is compatible
with clinical therapies.Introduction
Mesenchymal stem cells (MSC), sometimes also ad-
dressed as mesenchymal stromal cells, have been iso-
lated from many different tissues – and although some
differences may be found according to their origin, most
of them share their main features, including multipotent
differentiation and immunomodulation [1]. Irrespective
of the source of isolation, MSC have been found to be
able to modulate the immune response. This feature has
been extensively studied in vitro and in vivo in the past
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unless otherwise stated.for their efficacy in the treatment of many immune-
related diseases. Although MSC can be easily isolated
from tissues such as bone marrow, umbilical cord or
adipose tissue, it has been reported that these cells lose
their properties rapidly with time, undergoing cellular
senescence [2,3]. Moreover, it is possible that some ther-
apies will require large and repeated doses of MSC. In
the case that these therapies involve autologous MSC,
there would be some limitations in the number of repea-
ted procedures to obtain the cells. A limitless, economic
source of MSC would therefore be a valid alternative when
thinking in an autologous, off-the-shelf MSC therapy.
Platelet lysate (PL) is increasingly used instead of fetal
bovine serum (FBS) as a medium supplement for grow-
ing MSC. PL’s advantages have been described exten-
sively, and include its biocompatibility with cell therapy,
low cost, and easiness to produce [4,5]. PL contains a. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the platelets after lysing in the freeze/thaw cycles [6-8].
These growth factors are involved in many relevant
functions in stem cell biology, including basic fibroblast
growth factor, insulin-like growth factor and transform-
ing growth factor beta. Moreover, it has been demon-
strated that growing MSC in PL-supplemented medium
preserves the immunomodulatory ability of the cells [9].
PL supplement has been already used to grow MSC with
success, and these cells are used in clinical trials involv-
ing MSC without presenting any adverse reaction [10].
Pluripotent stem cells (PSC) can differentiate into any
type of adult stem cell. Interestingly, it has been reported
that PSC can derive into cells that share many features
with MSC isolated from adult tissues, and hence they
have been called pluripotent-derived mesenchymal stem
cells (PD-MSC) [11-13]. Many papers have described
different protocols to derive PD-MSC, and some of them
involve some complex manipulations or the use of cell
separation methods [14-22]. Even though they are called
mesenchymal cells, there are some disagreements bet-
ween some papers regarding the identity of PD-MSC,
and some authors consider that these cells are not re-
lated to MSC, based on their gene expression profile
[23]. In any case, PD-MSC have been analyzed in many
reports and they share many of the features of the adult
MSC, including surface markers, multilineage differenti-
ation and immunomodulation. Finally, there are some
reports that have analyzed their therapeutic potential,
and these cells have been shown to be very potent im-
munomodulators in animal models [24-27].
We have developed a method to derive PD-MSC using
PL as a media supplement (PD-MSCPL). This protocol gen-
erates a very significant number of PD-MSC within 3 to
4 weeks in a robust and consistent way. We believe that
this method can be scaled up at low cost to produce a sig-
nificant number of PD-MSCPL useful for clinical therapies.
Materials and methods
Cells and cell pluripotent stem cell culture methods
H9 human embryonic stem cells (hES) were purchased
from WiCell (Madison, Wisconsin, USA). Induced pluripo-
tent stem cells (iPS) were generated in our laboratory
(Maria Questa et al., unpublished observations) by standard
techniques. Briefly, foreskin fibroblasts were reprogrammed
by transfection with the STEMCCA lentivirus vector, gen-
erously obtained from Gustavo Mostovslasky [28]. Several
clones have been characterized in our laboratory by demon-
strating their pluripotent state and its ability to differentiate
into cells from the three germinal layers and by the forma-
tion of teratomas. For this paper, we have used both clones
FN2.1 and FH. PSC, either hES or iPS, are regularly grown
in our laboratory over inactivated (by radiation) mouse em-
bryonic fibroblasts, in Dulbecco’s modified Eagle’s medium(DMEM)/F12 medium supplemented with 10% Knock-Out
Serum Replacement, 8 ng/ml basic fibroblast growth factor,
and penicillin–streptomycin (all from Life Technologies,
Carlsbad, California, USA), under standard culture condi-
tions (37°C with a 5% carbon dioxide humidified atmos-
phere). Medium is changed daily. Human umbilical cord
mesenchymal stem cells (UC-MSC) were isolated from
Wharton jelly tissues. Derivation of UC-MSC was done
with due consent from the donor’s parents. Small pieces of
the umbilical cord, excluding the major vessels, were
layered onto plastic and cultured in alpha modified Eagle’s
medium supplemented with 10% PL and penicillin–
streptomycin. Fibroblasts were obtained from the foreskin
of a patient undergoing scheduled surgery, with informed
consent from the parents. These cells are grown in
DMEM supplemented with 10% FBS and antibiotics. All
isolations of primary cells were approved by FLENI Ethical
Committee after reviewing the research protocol.
Platelet lysate preparation
PL was produced with some modifications as described
previously [5]. Expired platelet bags were obtained from
the Hemotherapy Service of FLENI Foundation and fro-
zen at −80°C for at least 24 hours. The units were then
thawed at 37°C, pooled under sterile conditions, and fro-
zen again at −80°C. We prepared several batches, each
one containing at least 10 units of platelets obtained
from at least five different patients. Finally, the pooled
units were again thawed, aliquoted, and centrifuged at
3,000 × g for 30 minutes. The supernatant was stored
at −80°C until use. To use as a supplement, aliquots were
thawed and 2 IU/ml heparin (Sigma-Aldrich, San Luis,
Missouri, USA) were added before medium supplementa-
tion. Alternatively, we modified the protocol described by
Copland and colleagues for generating fibrinogen-
depleted PL [29]. In this protocol, fibrinogen is excluded
by adding 10 mM CaCl2 for 1 hour at 37°C. This step gen-
erates a dense clot; we then centrifuged the PL at 3,000 ×
g for 1 hour, collected the supernatant and froze it at −80°
C. We found no difference with either method of PL gen-
eration regarding the success of PD-MSC differentiation.
However, we prefer this later protocol since it avoids occa-
sional gelatinization of the medium and produced a sup-
plement with less debris without affecting results.
Pluripotent-derived mesenchymal stem cell differentiation
On day 0 of differentiation, PSC grown either on inactivated
mouse embryonic fibroblasts, Matrigel or Geltrex were in-
cubated with Accutase (Life Technologies) until cells were
completely dissociated, and were plated onto Matrigel-
coated plates (diluted 1/40; BD, San Jose, California, USA)
or onto Geltrex-coated plates (diluted 1/100; Life Tech-
nologies). Cells were resuspended in alpha modified
Eagle’s medium supplemented with 10% PL, penicillin–
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(Life Technologies). A Rho kinase inhibitor (10 μM
Y27632; Tocris, Avon, Bristol, UK) was added every time
the cells were passed until day 14 of differentiation. From
that day onward, cells were passed using trypsin on plastic
dishes with no coating, and were grown in medium sup-
plemented with 10% PL and penicillin–streptomycin. As
an alternative method of differentiation of PD-MSC, we
passed the cells in the same way but grew them in DMEM
supplemented with 10% FBS (PAA, Pasching, Austria)
plus penicillin–streptomycin. Characterization experi-
ments were performed after 30 days of differentiation and
up to three passages later, unless otherwise stated.
Fluorescent microscopy
Adherent cells were fixed with 4% paraformaldehyde at
room temperature for 45 minutes and then washed three
times with phosphate-buffered saline (PBS) with 0.1% bo-
vine serum albumin (BSA). Cells were then permeabilized
in PBS/BSA, 10% normal goat serum and 0.1% Triton for
45 minutes, and then washed again three times. Samples
were then incubated at 4°C overnight with either mouse
anti-OCT-4 (1:200, clone C-10; Santa Cruz, Dallas, Texas,
USA) or rabbit anti-NANOG (1:200, D73G4; Cell Signaling,
Danvers, Massachusetts, USA) primary antibodies in PBS/
BSA with 10% normal goat serum. After washing three
times with PBS/BSA, cells were incubated for 45 minutes at
room temperature with the corresponding secondary anti-
body (goat anti-mouse ALEXA-488, 1:100; Life Technolo-
gies) or goat anti-rabbit ALEXA-555 conjugated antibody
(1:100; Life Technologies) plus 0.1 μg/ml 4′,6-diamidino-2-
phenylindole. Cells were finally washed three times. Images
were acquired using a Nikon Eclipse TE2000-S inverted
microscope (Microlat, Buenos Aires, Argentina) and Eclipse
Net software (Microlat, Buenos Aires, Argentina).
Cell number quantification
PSC (1.5 × 105 cells) were initially plated at day 0 of the
protocol, on DMEM supplemented with either 10% PL
or 10% FBS. Cells were grown as described in the proto-
col. Every time the cells were passed, a 100 μl aliquot
was run through a BD Accuri cytometer and the cell
number concentration was determined.
Flow cytometry
Flow cytometry analyses were performed in a BD Accuri
cytometer. A standard protocol for cell staining was
used. Briefly, adherent cells were washed with PBS and a
single-cell suspension was obtained by incubating them
with Accutasse. Cells were then washed with PBS plus
0.5% albumin, and were incubated at room temperature
for 30 minutes with the appropriate antibody concentra-
tion. Cells were then washed with PBS plus 0.5% albu-
min and analyzed. At least 5,000 events were counted. Alist of the antibodies used in this paper is presented in
Table S1 in Additional file 1.
PCR and quantitative RT-PCR
Total RNA from cell extracts was isolated using Trizol
(Life Technologies) as described by the manufacturer.
Total RNA (1 μg) was retrotranscribed using MMLV
(Promega, Madison, Wisconsin, USA) and random primers
(Life Technologies). Quantitative RT-PCR was performed
using the Sybr Green ER qPCR Super Mix (Life Technolo-
gies) in a Step One Plus Real-Time PCR system (Applied
Biosystems, Foster City, California, USA). The list of the
primers used is presented in Table S2 in Additional file 1.
Multilineage differentiation of pluripotent-derived
mesenchymal stem cells
Multilineage differentiation potential was assessed using
the StemPro Adipogenesis, Osteogenesis or Chondro-
genesis Kit (Life Technologies) as per the instructions of
the manufacturer. After differentiation, adipogenesis in-
duction was assessed by Sudan Black staining. Briefly,
cells were fixed with 4% paraformaldehyde for 45 minutes
at room temperature, stained with a Sudan Black satu-
rated solution in 70% ethanol for 5 minutes at room
temperature, and finally washed thoroughly with 70%
ethanol. Osteogenesis induction was assessed by Alzarin
Red staining. Fixed cells were stained in a 2% Alzarin
Red solution (pH 4.2) for 3 minutes at room tempera-
ture and then washed thoroughly with distilled water.
Finally, chondrogenic induction was assessed by Alcian
Blue staining. Fixed cells were stained in a 1% Alcian Blue
solution prepared in 0.1 N HCl for 30 minutes at room
temperature and then washed thoroughly with distilled
water. All three preparations were visualized under a light
microscope. Images were acquired using a Nikon Eclipse
TE2000-S inverted microscope and Eclipse Net software.
Immunomodulation experiment
Peripheral blood mononuclear cells (PBMC) were isolated
from whole blood of healthy donors. Briefly, heparinized
blood samples were resuspended in PBS (1:1). Diluted
blood was then carefully layered on top of the Ficoll (Histo-
paque-1077; Sigma, San Luis, Missouri, USA) at a ratio of
1.5:1 and centrifuged at 800 × g for 30 minutes. The buffy
coat layer containing mononuclear cells was aspirated, and
the PBMC were then either cultured for immediate use in
RPMI-1640 (Gibco, Carlsbad, California, USA) supple-
mented with 10% FBS or frozen for later use. Before the
experiment, an appropriate number of PBMC were
stained with CFSE (Life Technologies) as described pre-
viously [30] and prestimulated with concanavalin-A
(Sigma) for 24 hours. Then, 1-day stimulated PBMC
were washed with PBS and cocultured with MSC for
96 hours in RPMI-1640 supplemented with 10% FBS,
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ml interleukin-2 (both from R&D Systems, Minneapolis,
Minnesota, USA). PBMC where then collected and ana-
lyzed by flow cytometry. In some cases, we stained the
PBMC for CD4 and CD8 antigens. Unstained PBMC,
stained but not stimulated PBMC and stained stimulated
PBMC without MSC were also run as controls.
Promoter methylation analysis
Genomic DNA was isolated using the Wizard Genomic
DNA kit (Promega). Then 200 ng DNA was methylated
using the EZ DNA Methylation Gold kit (Zymo Research,
Irvine, California, USA) as indicated by the manufacturer.
CpG islands in the OCT-4 promoter were amplified using
the primers presented in Table S2 in Additional file 1 [31].
PCR products were then purified using the ExoSAP-IT
(Affymetrix, Santa Clara, California, USA) and sequenced.
Semi-quantitative analyses were performed using the BiQ
Analyzer (Max Planck Institute for Informatics, Saar-
brücken, Germany) and BioEdit software (Ibis Biosciences,
Carlsbad, California, USA), measuring the relative inten-
sities of the curves from each CpG in the electrophero-
gram. For a comprehensive analysis, we built an intensity
graph where the 100% methylated CpG islands are
depicted in red and the 100% demethylated islands are
depicted in blue. All values in between are expressed by
grading the intensity of the corresponding color.
Statistical analysis
We analyzed continuous variables using the Student t test.
The significance level was set at 0.05. Data are expressed
as mean ± standard deviation.
Results
PL has been shown to include a significant amount of
growth factors [6,7,32,33]. We first tested whether these
signals would induce differentiation of PSC. The PSC were
grown on either inactivated mouse embryonic fibroblasts
or Matrigel-coated plates, and Knock-Out Serum Replace-
ment was replaced by PL 10% without basic fibroblast
growth factor. This experiment resulted in a rapid differ-
entiation of the pluripotent colonies. As seen in Figure 1,
colonies adopted a clear differentiated morphology after
4 days, with irregular shapes of the colonies and cells with
increased cytoplasm. We then measured the expression of
PSC transcription factors by quantitative RT-PCR, includ-
ing OCT-4 and NANOG, and found that they significantly
declined after 4 days. Finally, we stained PSC colonies for
these same pluripotent markers and we found that their
expression was lowered or mostly absent by this time. We
believe that the significant amount of growth factors in-
duce a rapid differentiation of the PSC, even though we
cannot discard the possibility that differentiation towardsmesenchymal cells is mainly driven by the lack of
pluripotency-supporting conditions.
We then designed a protocol for differentiating PSC into
MSC using PL as cell culture media supplement. After test-
ing several conditions (results not shown), we designed a
two-stage protocol (Figure 2A). In the first part, cells tran-
sition from the pluripotent stem state to a mesenchymal
lineage. During this transition, these cells still require some
signals to provide the suitable support to survive. For ex-
ample, at this stage it is necessary to use a ROCK inhibitor
(we use Y-27632 at a concentration of 10 μM) to avoid a
massive cell death after plating. We noted that cells were
very sensitive at this stage to enzyme dissociation. We then
use Accutase for approximately 7 to 10 minutes, enough to
dissociate cells to a single cell level [34]. We also observed
that a cell surface coating is required. We use Matrigel (di-
luted 1/40 to 1/60) or Geltrex (diluted 1/100) with similar
results. We also tried gelatin-coated plates, but this was in-
effective. It is also possible to coat the plate with a gelatin
formed with PL resuspended in DMEM, without adding
heparin. In approximately 1 hour a light gelatin is formed,
which can be easily aspirated leaving a coating at the bot-
tom. We found this coating a good alternative for the first
stage of the protocol. Finally, we also add the supplement
B27 in this first stage, diluted 1/100. During this stage, cul-
ture media was changed every other day and cells were
passaged when reached approximately 70 to 80% conflu-
ence (usually, three to four times in this period). After ap-
proximately 14 days, cells have already transitioned to a
mesenchymal state, and the cells become less stringent
with the cell culture conditions. From this time point we
supplement the medium only with PL 10%, and cells can
be passed in a regular way over noncoated plates.
As soon as 24 hours after starting the protocol the cell
morphology rapidly changed (Figure 2B), gaining cyto-
plasm and adopting a rounded form, although they re-
mained attached in small colonies. After a few days these
cells begin to separate, and after a few weeks they finally
changed to a fusiform shape by 3 to 4 weeks. During this
time, the cells continued to grow at a fast rate, and it
was necessary to pass them frequently. We analyzed
the PD-MSCPL after 30 days of differentiation (and up
to three passages later) for several MSC surface markers.
These cells strongly expressed the classical MSC markers
CD90, CD73 and CD105. They also stained positive for
other known MSC markers, including CD166, CD172
alpha, and CD271 and integrins (CD29, CD49a, CD49d,
CD49e, CD49f and CD51/61). We also found that these
cells are negative for several cell surface markers, in-
cluding CD11b, CD14, CD19, CD34, CD45, CD79a,
CD309 and HLA-DR (data not shown). These cells there-
fore expressed those MSC surface markers that are usually
found in MSC isolated from other sources. Finally, we also
differentiated PD-MSC using FBS as supplement instead
Figure 1 Use of platelet lysate prompts pluripotent stem cells towards differentiation. (A) Optical microscopy of pluripotent stem cells
(PSC) cultured during 4 days in either standard growth condition (control) or platelet lysate-supplemented medium (PL). Cells gain cytoplasm and
differentiation zones are observed. (B) mRNA levels of OCT-4 and NANOG in PSC cultured during 4 days in control (CM) or PL, assessed by
quantitative PCR. A rapid decline in pluripotent transcription factors is seen (*P <0.05). (C) Fluorescence microscopy of 4′,6-diamidino-2-phenylindole
(DAPI), OCT-4 and NANOG in PSC cultured as mentioned above. A faint stain for OCT-4 is observed, whereas no expression of NANOG is found.
Luzzani et al. Stem Cell Research & Therapy 2015, 6:6 Page 5 of 13
http://stemcellres.com/content/6/1/6of PL (PD-MSCFBS); these cells expressed similar surface
markers to PD-MSCPL after 3 to 4 weeks.
In our experiments we noticed that all of the diffe-
rentiation process takes approximately 3 to 4 weeks to
complete. Interestingly, the growth rate with PL supple-
ment was very high (Figure 3), and was considerably
higher than that for similar cells derived with FBS. When
both supplements were compared, PL was able to produce
approximately as many as 25 cells per each PSC after
2 weeks in culture; this number is usually approximately
10 cells when FBS was used as supplement. We then tem-
porarily analyzed the differentiation process looking for
a specific point where the cells mature to a PD-MSCPL
population. We first analyzed PSC markers by quantita-
tive RT-PCR (Figure 4A). We found that these markersgradually disappeared, and by day 21 the expression
was insignificant. We also assessed for markers of the
epithelial-to-mesenchymal transition, as this process
must necessarily occur. SNAI2 and ZEB2, two tran-
scription factors critical for epithelial-to-mensenchymal
transition, significantly increased after a few days of
starting the protocol. T/Brachyury was also significantly
elevated, but gradually disappeared after a week, as it
usually occurs in mesoderm differentiation. Finally, the
mesenchymal marker vimentin was found significantly
increased at later stages of the differentiation.
We also analyzed the temporal evolution of the mes-
enchymal differentiation by flow cytometry (Figure 4B).
We built several panels of cell surface markers. First, we
assessed a two-color panel including MSC marker CD90
Figure 2 Use of platelet lysate differentiates pluripotent stem cells towards a mesenchymal phenotype. (A) Scheme of the differentiation
protocol used in this work. (B) Microscopic view of the cell’s phenotype progression during protocol. Cells progressively gain cytoplasm and
separate from each other. (C) After protocol completion, cells are positively stained for mesenchymal stem cell surface markers, analyzed by flow
cytometry. Red, cells stained for the indicated marker; black, unstained control. PL, platelet lysate.
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specific PSC marker. We found that Tra-1-60 gradually
disappeared, and by day 10 was absent. CD90 expression
was also slightly reduced after 3 weeks of differentiation,
but remained significantly expressed during all of the
differentiation time. We then analyzed a three-color
panel, gating at CD90+cells, and staining for CD73 andCD105, both classical markers of MSC. We found a steady
increase in the expression of both markers. However, it
was not until day 21 that most cells were CD90+CD73+
CD105+. Finally, we built two other three-color panels
(CD90/CD172alpha/CD49d and CD90/CD172alpha/CD49a;
data not shown). Again, cells become triple positive ap-
proximately by day 21 for these markers. In summary,
Figure 3 Platelet lysate supplement increases the yield of
mesenchymal stem cells derived. Initially, 1.5 × 105 pluripotent
stem cells were plated and cultured in medium supplemented
either with 10% fetal bovine serum (FBS) or 10% platelet lysate (PL).
At the indicated days, cells were passed and counted in a flow
cytometer. From day nine onwards, PL supplement generates
substantially more cells than FBS (*P <0.05). PD-MSCFBS, pluripotent-
derived mesenchymal stem cells supplemented with fetal bovine
serum; PD-MSCPL, pluripotent-derived mesenchymal stem cells
supplemented with platelet lysate.
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sion pattern, and temporal expression of cell surface
markers, we conclude that it takes from 14 to 21 days at
least for the PSC to differentiate into PD-MSCPL. We then
considered fully differentiated PD-MSCPL with those cells
obtained after 28 days of differentiation, and used them
for characterization in the next experiments.
We then analyzed the functional properties of the
PD-MSCPL. We first tested whether PD-MSCPL present
multipotent properties. As can be observed in Figure 5A,
these cells differentiate into chondroblasts, osteoblasts
and adipocytes. After 2 to 3 weeks in the corresponding
differentiating media, the cells stained positive for each
tissue. We then performed a lymphocyte proliferation
assay (Figure 5B) and found that PD-MSCPL present
in vitro immunomodulating ability. After 4 days in co-
culture with PD-MSCPL, there was a significant reduction
in lymphocyte proliferation. As expected, PD-MSCFBS also
present similar immunomodulating properties (data not
shown). We further extend our findings by analyzing the
subset population of CD4+ and CD8+ lymphocytes and
found that PD-MSCPL are able to significantly reduce the
proliferation of both cell types.
We finally compared the identity of the PD-MSC dif-
ferentiated using this protocol with other related cells.
For this purpose, we compared the properties of PD-
MSCPL with fibroblasts, PD-MSCFBS, UC-MSC and PSC.
The pluripotent stem cell FN2.1 was used as baseline.
We first assessed the expression of several markers re-
lated to mesenchymal cells, particularly the expression
of extracellular matrix proteins. By quantitative RT-PCRwe measured the expression of collagen (COL4A1), fi-
bronectin, laminin (the subunit lamb1) and vimentin.
Although there was some variation in the expression, we
can conclude that PD-MSCPL resemble UC-MSC more
than they resemble fibroblasts, and are different to PSC,
as expected (Figure 6A). We then analyzed the expres-
sion of surface markers in each of these populations
(Figure 6B). Most MSC markers are shared between these
populations, including fibroblasts, and we could not find
any specific surface marker that could distinguish PD-
MSCPL from UC-MSC. We could indeed identify some
markers that varied from the mesenchymal state to the
pluripotent state, and vice versa. These markers include
the MSC markers and PSC markers. We also performed
panel of integrin expressions in these cells (Figure 6;
Additional file 2). The integrin expression profile of
PD-MSCPL is similar across the mesenchymal cells, but
some differences are found with PSC. A profile of the
cell surface markers is summarized in the Table 1. Fi-
nally, it has been described that the methylation state
of the promoter region of the pluripotent gene OCT-4
switches from fibroblast to iPS; also, the OCT-4 pro-
moter is partially methylated in UC-MSC [35-37]. We
then assessed all our cell populations for the demethyl-
ation state of the promoter of OCT-4 (Figure 6C). We
found that this region is mostly demethylated in PSC,
as expected in those cells where OCT-4 is highly ex-
pressed. The average level of demethylation was similar
for both hES and iPS. However, PD-MSCPL presented a
mostly methylated state of the promoter of OCT-4. The
degree of demethylation was similar to all other MSC,
and particularly no different to fibroblasts. Again, these
findings support that PD-MSCPL are similar to other
MSC, and to some extent similar to fibroblasts.
Discussion
We present in this paper a detailed protocol to derive
MSC from PSC. Our protocol involves simple steps, and
generates a significant amount of cells in approximately
1 month. The main feature of this new protocol is the
use of a therapy-grade supplement, PL. This supplement
is easy to produce in great quantities, and it allows a sig-
nificant expansion of the mesenchymal cells. We pro-
duced and tested several PL batches, and there seems to
be no differences in the final product in terms of the
ability to generate PD-MSCPL, although this should be
formally tested. However, other papers analyzed the dif-
ferences in batches and found that they all present simi-
lar results [38,39]. We also tested several hES and iPS
cell lines, with similar results in all of them. We there-
fore conclude that the method is reliable enough to be
applied in different settings.
PD-MSC are somehow intriguing. Since their descrip-
tion in 2005, many investigators have characterized a
Figure 4 Kinetics of the epithelial-to-mesenchymal transition during mesenchymal stem cell derivation. (A) mRNA levels of the
pluripotent markers OCT-4 and NANOG along the PD-MSCPL derivation protocol, assessed by quantitative PCR. (B) mRNA levels of the epithelial-
to-mesenchymal transition markers Snai-2 and Zeb-2, the mesoderm marker T/Brachyury, and the mesenchymal marker Vimentin along the
mesenchymal stem cell (MSC) derivation protocol, assessed by quantitative PCR. (C) Evolution of CD90/TRA-1-60, CD73/CD105 and CD172a/CD49d
during the PD-MSCPL derivation protocol, assayed by flow cytometry. These data point to a slow transformation of pluripotent stem cells into MSC,
taking approximately 2 to 3 weeks to complete. PD-MSCPL, pluripotent-derived mesenchymal stem cells supplemented with platelet lysate.
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many features of MSC. Moreover, an early publication
on the culture of PSC over different matrixes described
the outgrowing of fibroblastoid cells, which gave nutri-
tional support to PSC [40-42]. These cells were probably
PD-MSC, although they were not characterized as MSCshould be. We then hypothesized that it is an intrinsic
feature of PSC to differentiate into a mesenchymal state
whenever adverse conditions for staying as PSC are
found. We did not address this hypothesis, although an
interesting observation supporting it is that we do not
see a significant apoptotic rate while the proper culture
Figure 5 Pluripotent-derived mesenchymal stem cells supplemented with platelet lysate are fully functional. (A) Optical microcopy of
PD-MSCPL differentiated to an adipogenic (a), chondrogenic (b) or osteogenic (c) lineage. (B) Immunomodulation assay. Stimulated peripheral
blood mononuclear cells (PBMC) stained with carboxyfluorescein succinimidyl ester (CFSE) show normal proliferation in the absence of
mesenchymal stem cells (MSC) (a, left panel) but a reduced proliferation of activated PBMC when cocultured with PD-MSCPL (a, middle panel)
compared with that of nonactivated PBMC (a, right panel) in a representative experiment. When stained for CD4 and CD8 lymphocyte
populations, a similar finding is seen. Statistical analysis shows significant difference in proliferation from the third doubling onwards (**P <0.1;
*P <0.05). PD-MSCPL, pluripotent-derived mesenchymal stem cells supplemented with platelet lysate.
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undergo differentiation end up in a mesenchymal state.
As opposed to embryoid body generation where the three
germinal layers are generated, this procedure – which
shares the unspecificity of the wide combination of growth
factors that FBS or PL contains – yields only mesenchy-
mal cells. It remains to be determined what feature of
this process drives the differentiation to mesenchymal
cells (that is, two-dimensional vs. three-dimensional
culture conditions).PL has been used for many years as a medium supple-
ment. PL became popular a few years ago for growing
MSC due to its effectiveness and low cost. PL has shown
some advantages compared with FBS, such as the greater
growing rate when MSC are grown with PL. We also
found a similar result, but in our case we found that the
PL supplement significantly increased the number of dif-
ferentiated cells. Regarding costs, PL is discarded once
platelet units expire, which is usually after 5 days of isola-
tion. Many biocompatible mediums are based on defined
Figure 6 (See legend on next page.)
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Figure 6 Pluripotent-derived mesenchymal stem cells supplemented with platelet lysate are similar to other mesenchymal stem cells
and different to pluripotent stem cells. (A) mRNA levels of extracellular matrix components in human foreskin fibroblasts (fib), induced
pluripotent stem cells (iPS), PD-MSCPL, PD-MSCFBS and umbilical cord mesenchymal stem cells (UC-MSC). (B) Expression of mesenchymal stem cell
markers in the indicated cell lines. Red, stained cells; black, unstained control. (C) Demethylation levels in all cell lines. Each square represents a
CpG. Numbers indicate base positions relative to the transcription start site and delimit a CpG island. Globally, the OCT-4 promoter region was
found demethylated in human embryonic stem cells (hES) and iPS, whereas all of the mesenchymal stem cells and fibroblasts showed it mostly
methylated. FBS, fetal bovine serum; PD-MSCFBS, pluripotent-derived mesenchymal stem cells supplemented with fetal bovine serum; PD-MSCPL,
pluripotent-derived mesenchymal stem cells supplemented with platelet lysate; PL, platelet lysate.
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considered for a significant scale up in cell production.
With PL, a single batch of 10 units would produce an
amount of supplement enough for 5 to 10 l of medium.
Scaling up then would not be problematic. A potential dis-
advantage of PL, however, is the potential biological risk.
Platelet units may contain virus (that is, HIV, cytomega-
lovirus, and so forth) or parasites (that is, Tripanozoma
cruzii in our country), which may be transmitted to a po-
tential recipient if cells are then used in clinical treat-
ments. Although the risk is minimal after the current
protocols for blood testing are properly applied, the risk is
not zero. However, it is currently unclear whether this risk
surpasses the risk of using FBS, considering potential
problems of using an animal-derived product in humans.
In any case, blood derivate transfusion is broadly expan-
ded without major problems with transmissible diseases,
and PL supplement has been applied in clinical trials
using MSC. Recently, Frobel and colleagues analyzed theTable 1 Comparative cell surface expression pattern of the di
pluripotent stem cells
Fibroblasts
Mesenchymal stem cell markers CD90 +++
CD73 ++
CD105 ++
CD166 +++
CD172alpha +
CD271 –
Pluripotent stem cell markers Tra-1-60 –
CD133 –
CD309 –
Integrins CD29 +++
CD49a +++
CD49d +++
CD49e +++
CD49f +++
CD51/61 +++
Markers are grouped according to phenotype. No major difference was found betw
are useful to distinguish between PSC and mesenchymal cells. –, no expression; +,
pluripotent-derived mesenchymal stem cells supplemented with fetal bovine serum
platelet lysate; PSC, pluripotent stem cells; UC-MSC, umbilical cord mesenchymal stepigenetic changes during redifferentiation of PSC to-
wards MSC using PL [43]. Notably, they found that
PD-MSC seem to provide a more standardized source
of MSC due to epigenetic resetting during cell repro-
gramming, but they proposed that these cells have to
be more thoroughly assessed.
We found significant immunomodulatory properties
of these cells. We performed a lymphocyte proliferation
test where PD-MSCPL were found to significantly reduce
the immune activation. Even though this is a common
feature in all MSC, we performed a test with prestimu-
lated lymphocyte. A previous publication found that
UC-MSC were not able to reduce the immune response
when lymphocytes were prestimulated, as in our experi-
ment [44]. The reason why we prestimulated the lym-
phocyte was that we found concanavalin-A was toxic for
PD-MSCPL. It remains to be determined whether this is
a particular effect in PD-MSCPL, since concanavalin-A
toxicity has not been reported with other MSC. In anyfferent mesenchymal stem cells analyzed, fibroblasts and
PSC PD-MSCPL PD-MSCFBS UC-MSC
+++ +++ +++ +++
– +++ +++ +++
– +++ +++ +++
– +++ +++ +++
– + + ++
+ + + +
+++ – – –
+++ – – –
++ – – –
+++ +++ +++ +++
– +++ + ++
– +++ +++ +++
+++ +++ +++ +++
+++ +++ +++ +++
– +++ +++ +++
een fibroblasts, PD-MSCPL, PD-MSCFBS and UC-MSC. Some markers, however,
mild expression; ++, medium expression; +++, strong expression. PD-MSCFBS,
; PD-MSCPL, pluripotent-derived mesenchymal stem cells supplemented with
em cells.
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not able to immunomodulate prestimulated lympho-
cytes. The case for a significant immunomodulation of
PD-MSC has also been found in other papers. Recently,
Kimbrel and colleagues and Wang and colleagues repor-
ted that PD-MSC are very potent immunomodulators,
and are even able to improve outcomes in a sclerosis mul-
tiple mouse model, which is typically resistant to MSC
from other sources [26,45]. These findings support previ-
ous reports where PD-MSC where found to be effective in
modulating the lymphocyte proliferation, but also to regu-
late the natural killer cell response, an effect not observed
with bone marrow-derived MSC [24,25]. In summary, our
experiments support the concept that PD-MSC are at
least as potent as other MSC for immunomodulation.Conclusions
We describe an easy, low-cost, therapy-grade protocol
to generate a significant number of PD-MSC. We be-
lieve this protocol could be applied in therapies in which
autologous iPS are generated and then large numbers
of MSC are produced, and this process could be prefer-
able instead of multiple bone marrow aspirations or fat
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